Chronic Care

Oral semaglutide had a safe and well-tolerated profile for individuals with type 2 diabetes, which is in line with those previously reported for the drug in other trials.

Bezisterim, an anti-inflammatory insulin sensitizer, will be authorized to proceed to a phase 2 clinical trial.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

The efficacy data are consistent with other phase 3 studies, reinforcing lebrikizumab's potential as a first-line treatment across a range of skin tones.

The findings also indicated that individuals who experienced significant adverse events in childhood were approximately 17% more likely to experience adverse events in adulthood.

The data follow the FDA approval of omalizumab for the reduction of allergic reactions, including anaphylaxis, that can occur after exposure to 1 or more foods.

This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.

Mouthwash that contains chlorhexidine gluconate was especially effective at improving hyperglycemic status in younger patients with diabetes.

Inadequate levels of zinc, vitamin D, vitamin E, and vitamin B were also associated with risk of diabetes or diabetes-related complications.

Migraines are not a one-size-fits-all condition, and there is no one-size-fits-all solution.

IVIg treatment may need to be given proactively both throughout the duration of anti-BCMA bispecific antibody therapy and afterward.

Functional exercise resulted in more improvements for individuals with PCC compared to standard treatment, although individuals must be monitored for adverse events.

Infections were associated with a 1.49-fold increase in the rate of dementia in both the short- and long-term rates, however, the increases were greater in the short term.

KARDIA-1 study met its primary and secondary endpoints, and the drug maintained a positive tolerability profile treating high systolic blood pressure.

After identifying the CHD1L gene, investigators explored the biological mechanism for the genetic association in those of African descent, determining the gene limits HIV replication in a subset of white blood cells.

The collaboration will focus on engaging with health experts and opinion leaders to examine data to gain a better understanding of the role continuous glucose monitoring systems have in personalized therapeutic nutrition.

Treatment with Injectafer significantly improved exercise capacity compared to placebo in a randomized clinical trial in adult patients with heart failure.

A new FDA policy would assess blood donor eligibility using a set of individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

Lack of awareness, or anosognosia, may be present up to 2 to 3 years before an Alzheimer dementia diagnosis is made.

The risk is particularly high in the first 2 years after an HIV diagnosis.

Persistently pursuing valued goals and adjusting those goals in response to setbacks or obstacles may help explain how some individuals with chronic pain maintain their mental wellbeing.

Migraine could be considered a clinical marker of increased obstetric risk in pregnant women.

The supplemental new drug application is based on results from a landmark phase 3 trial showing that empagliflozin tablets provided meaningful results.

Research looking at neurofeedback and “chemo brain” found that most patients had normal brain function after 18 weeks of neurofeedback therapy, significantly improving patient symptoms.

A new e-learning program could enable nurses to better evaluate and manage pain in neonates, according to investigators at Hiroshima University.

The new educational content series for nurses treating patients with pulmonary hypertension and pulmonary arterial hypertension is set to be more unique than other programs.

Pre-exposure prophylaxis can effectively reduce the risk of HIV transmission.

According to National Institutes of Health estimates, between 70% and 90% of individuals in the United States who have injected drugs for 10 years or more are infected with HCV.

Navitoclax is an investigational, oral BCL-XL/BCL-2 inhibitor that is designed to activate programmed cell death in cancer cells.